Breakfast Seminar – Insights from the Japanese Life Science Market

Did you know that Japan is one of the most important overseas markets for Swedish life science?

Japan’s vast and homogeneous healthcare system continues to be a vital source of revenue for leading Swedish companies such as AstraZeneca, Getinge, and Elekta, while also attracting innovative newcomers like Sobi and SyntheticMR. Beyond trade, Japan is also a key partner in biotech collaboration. Recent examples of Sweden-Japan life science collaboration include BioArctic-Eisai and Cantargia’s USD 613 million CAN10 agreement with Otsuka announced in July 2025

Join us for an insightful seminar where we’ll explore:

•The latest developments and trends in Japan’s life science sector, such as Japan’s Ministry of Health, Labour and Welfare approved the world’s first induced pluripotent stem cell (iPSC)-derived therapies

•Opportunities for Swedish companies in pharmaceuticals, medtech, and biotech, digital health and beyond

•How we can support your journey into the Japanese market

•Preview of opportunities at Nordic Health Summit Japan in April 2027

Let us help you unlock the potential of Japan’s life science landscape

Register: By contacting Christina.Wenglen@skane.se